BioStock: Aptahem on schedule for clinical studies

Malmö-based biotech Aptahem, which is developing the drug candidate Apta-1 as a new type of emergency treatment for sepsis, released its Q2 report last week. It is clear that the company, which is approaching the first in-human studies, is so far on schedule and that more and more details are falling into place for the upcoming clinical work.

Read the article at biostock.se:

https://www.biostock.se/en/2022/08/aptahem-on-schedule-for-clinical-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/